Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$187.5KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sabrina Martucci Johnson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Beta
- 1.01
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -13.39
Financials
Revenue
$187.5K-75.5%Net Income
$-2.98MEBITDA
$-2.95M-4860.4%Free Cash Flow
$-6.86MEPS (diluted)
$-0.20Shares Outstanding (diluted)
14.89M+443.8%Operating Expenses
$2.84MCash & Debt
$12.62MRevenue by Segment (annual)
$12.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.03M | $-13.40M | $-1.20 |
| 2024 | $9.8K | $-4.05M | $-0.48 |
| 2023 | $2.81M | $-30.16M | $-4.15 |
| 2022 | $10.00M | $-30.95M | $-4.39 |
| 2021 | $0.00 | $-38.70M | $-7.52 |
| 2020 | $0.00 | $-27.40M | $-10.93 |
| 2019 | $0.00 | $-14.26M | $-10.99 |
| 2018 | $0.00 | $-16.74M | $-30.16 |
| 2017 | $0.00 | $-11.50M | $-3.56 |
| 2016 | $766.0K | $-39.30M | $-30.02 |
| 2015 | $0.00 | $-39.59M | $-15.57 |
| 2014 | $80.0K | $-23.34M | $-192.00 |
| 2013 | $6.0K | $-17.14M | $-108.19 |
| 2012 | $625.0K | $-22.10M | $-280.83 |
Valuation
DAREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·8d ago·Neutral
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection
View source ↗ - Newsglobenewswire.com·36d ago·Positive
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series Video webcast now available here
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
View source ↗ - Newsglobenewswire.com·41d ago·Positive
…l systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA's 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value over the next 12–18 months Access the segment here
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·53d ago·Neutral
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.45 per share a year ago.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.14 per share
Typical surprise +20.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.20 vs $-0.30beat
- Thu, May 14$-0.20 vs $-0.33beat
- Thu, Mar 26$-0.02 vs $-0.24beat
- Thu, Nov 13$-0.28 vs $-0.33beat
- Thu, Aug 14$-0.45 vs $-0.55beat
- Tue, May 13$-0.50 vs $-0.63beat
Estimates and results for DARE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DARE officers and directors.
- Bought
- $500k
- Sold
- —
1 trade
0 trades
- Hawley Rogerbought
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DARE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.